News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Factor That Could Determine Future Breast Cancer Treatment, Garvan Institute of Medical Research Study


12/28/2012 7:44:15 AM

ustralian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors. Transcription factors are molecules that switch genes on or off. In this case, the transcription factor known as 'ELF5' inhibits sensitivity to oestrogen very early in the life of a breast cancer cell. In 2008, Associate Professor Chris Ormandy from Sydney's Garvan Institute of Medical Research showed that ELF5 was responsible for the development of the oestrogen-receptor-negative cells in the breast during pregnancy that produce milk.

Read at EurekAlert!
Read at ScienceBlog

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES